Delving into the Latest Updates on Ciclopirox olamine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Ciclopirox Olamine Cream, Ciclopirox Olamine Gream, Ciclopirox Olamine Vaginal Suppositories

+ [13]

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesSkin and Musculoskeletal DiseasesUrogenital Diseases+ [2]

Active Indication

Candidiasis, VulvovaginalDermatitis, SeborrheicMycoses+ [2]

Inactive Indication

Tinea Pedis

Originator Organization

Medimetriks Pharmaceuticals, Inc.

Active Organization

Hubei Ke Tian Pharmaceutical Co. Ltd.

Kafrelsheikh University

Louisiana State University Health Shreveport

+ [1]

Inactive Organization

Perrigo Co. Plc

Drug Highest PhaseApproved

First Approval Date

Canada (01 Jan 1985)

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC14H24N2O3

InChIKeyMBRHNTMUYWQHMR-UHFFFAOYSA-N

CAS Registry41621-49-2

View All Structures (2)

A review.Pyridine-based ring structures are widely employed in drug design due to their significant impact on pharmacol. activity, resulting in the development of various broad-spectrum therapeutics.The US FDA approves 95 pharmaceuticals derived from pyridine, including isoniazid and ethionamide for tuberculosis, delavirdine for HIV/AIDS, abiraterone acetate for prostate cancer, tacrine for Alzheimers, ciclopirox for ringworm and athletes foot, crizotinib for cancer, nifedipine for Raynauds syndrome and premature birth, piroxicam for arthritis, and nilvadipine for hypertension.Moreover, pyridine derivatives act as an excellent candidate for targeted anticancer agents.However, pyridine anti-cancer therapies continue to encounter hurdles, including poor response rates and drug resistance.Researchers are exploring pyridine derivatives as a potential treatment for targeted anticancer therapies.To further the development of targeted anti-cancer therapies, we analyzed pyridine-targeted drugs based on target categorization.We have covered all researchers of the last six years (2019-2024) investigating pyridine derivatives as targeted anticancer treatments.The highlights of pyridine-containing drugs and their targets are listed, as well as most promising drug candidates in clin. trials containing pyridine are also discussed.This review also included explanatory insights and viewpoints from several groups involved in the creation of targeted anticancer pyridine derivatives, with an emphasis on the structure-activity relationship (SAR).We hope that the current review provides insights and perspectives for the research and development of pyridine-containing anti-cancer drugs.

01 Nov 2024·Computational and Theoretical Chemistry

The computational investigation of the role of pristine and metal-doped BC2N nanotubes for sensitive detection of ciclopirox drug

Author: Jassim Al-saray, Mustafa ; Muhi Hariz, Hussein ; Ahmed Said, Esraa ; Salih Jumaa, Sally ; Yadav, Anupam ; Kadhim Abosaoda, Munther ; Mohammed Ali, Yusra ; Abdulhadi Khuder, Shahad ; Ahmed Mustafa, Mohammed ; Muzahem Al-Ani, Ahmed ; Malik, Abdul ; Atiyah Altameemi, Kamil K.

Even though Ciclopirox (CPX) plays a critical role in the treatment of pancreatic, colorectal, and breast cancers, some side effects are attributable to CPX.Thus, determining the content of CPX in biol. specimens is criticalThe contribution of CPX to the activity of the intrinsic and Au-decorated BC2N nanotubes (BC2NNT) has been analyzed in this research by employing d. functional theory estimationsAccording to the results, the gold decoration resulted in a noticeable improvement in BC2NNT toward CPX and increased value of BC2NNT sensing response from 9.3 to 307.1.Furthermore, a short recovery was allowed (approx. 1.12 s) in order to desorb CPX from the Au@BC2NNT exterior.The CPX-Au@ BC2NNT interaction decreased in the aqueous solution, which led to a declined Au@BC2NNT sensing response from a value of 307.1 to 260.0.However, in accordance with our results, by employing the gold-doping process, one may transform BC2NNT into an appropriate sensor for CPX.

01 Nov 2024·Mycoses

First Reported Cases of Terbinafine‐Resistant Trichophyton indotineae Isolates in Israel: Epidemiology, Clinical Characteristics and Response to Treatment

Author: Shemer, Avner ; Lyakhovitsky, Anna ; Segal, Oz ; Halevi, Shiraz ; Pevzner, Keren ; Gazit, Zeala ; Baum, Sharon ; Lubitz, Irit ; Amit, Sharon ; Galili, Eran ; Astman, Nadav ; Barzilai, Aviv

ABSTRACTBackgroundTrichophyton indotineae, a newly defined species within the T. mentagrophytes/T. interdigitale complex, has emerged as an epidemiological concern worldwide. However, owing to the limitations of commonly applied fungal identification techniques, T. indotineae remains underreported. In addition, T. indotineae's response to treatment has been described in only a few studies.ObjectiveTo investigate the prevalence, clinical characteristics and treatment outcomes of terbinafine‐resistant T. mentagrophytes/T. interdigitale complex infections, as well as to detect T. indotineae cases.Patients and MethodsA retrospective cohort study was conducted on 22 patients with T. mentagrophytes/T. interdigitale complex infections between 2019 and 2023, using either culture or commercial polymerase chain reaction methods. Patient demographics, disease characteristics and treatment responses were recorded. Patients non‐responsive to oral terbinafine underwent further analyses, including DNA sequencing of the internal transcribed spacer region for accurate species identification and mutational analysis of the squalene epoxidase (SQLE) gene.ResultsThe mean age of the patients was 49.7 years (±18.2), with 54.5% men. Terbinafine‐resistant T. mentagrophytes/T. interdigitale complex infections were reported in 46.2% of the cohort (n = 6/13 patients; 9 lost to treatment response follow‐up), all of whom exhibited extensive dermatophytosis. Among the terbinafine‐resistant T. mentagrophytes/T. interdigitale isolates, all five isolates available for fungal analysis were identified as T. indotineae, harbouring SQLE single‐point mutations (Phe397Leu and Leu393Ser). Only three of the terbinafine‐resistant cases responded to oral itraconazole 200 mg/day, with two responding only to oral voriconazole and one to oral itraconazole 400 mg/day.ConclusionAll cases of T. mentagrophytes/T. interdigitale assessed in this study were identified as T. indotineae, which exhibits SQLE gene mutations. This underscores the importance of integrating methods to detect T. indotineae in routine clinical practice.

100 Deals associated with Ciclopirox olamine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01364	Ciclopirox olamine	D01AE14 G01AX12	DBSALT001147

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Candidiasis, Vulvovaginal	China	Hubei Ke Tian Pharmaceutical Co. Ltd.	01 Jan 1989
Dermatitis, Seborrheic	China	Hubei Keyi Pharmaceutical Co., Ltd.	01 Jan 1989
Mycoses	China	Hubei Ke Tian Pharmaceutical Co. Ltd.	01 Jan 1989

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Preclinical	Egypt	Kafrelsheikh University	07 Oct 2024
Neoplasms	Discovery	United States	Louisiana State University Health Shreveport	15 Apr 2012
Tinea Pedis	Discovery	-	Perrigo Co. Plc	01 Dec 2003

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASN2019	Not Applicable	Polycystic Kidney Diseases	-	Ciclopirox-Olamine	adkwvwafms(gvagcbbtcp) = xyolmzvcag qxcriexuxc (rhuhgznxqa ) View more	Positive	05 Nov 2019
NCT00804193 (CTgov)	Not Applicable	Tinea Pedis	553	Ciclopirox Olamine Topical Suspension (Test Product)	tykfydjwsg(rubvinwckd) = kgltetndjq adlzordrif (nehtctugou, cdyectsdkq - ydcnonftit) View more	-	17 Dec 2012
				Ciclopirox Topical Suspension 0.77%-Reference Product (Reference Product)	tykfydjwsg(rubvinwckd) = fqyphxhdji adlzordrif (nehtctugou, wmdqujdapn - txvykfhmtx) View more
NCT00802672 (CTgov)	Phase 3	Tinea Pedis	561	Ciclopirox Olamine Cream (Test Product)	biayidtxnx(xvmvjwgtnp) = ghienxainx vghrgnuesp (afycoqddxb, qstyairlci - axniljercc) View more	-	19 Jun 2012
				Loprox Cream 0.77% (Reference Product)	biayidtxnx(xvmvjwgtnp) = ckiblzrniq vghrgnuesp (afycoqddxb, nqfoicfakv - pmrspgvfui) View more